A Phase 2 interventional study of Benralizumab and Placebo and Benralizumab in Chronic Spontaneous Urticaria, sponsored by AstraZeneca. Terminated at 40 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-03-13.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 26th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 in phase 2, and was the 29th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 1 study filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT06931405Blueprint Medicines CorporationStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
The aim of this study is to investigate the use of benralizumab as treatment for patients with chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines. It is proposed that benralizumab will deplete eosinophils and basophils from affected skin, improve symptoms of CSU, and improve CSU-related quality of life. This Phase 2b study is designed to evaluate induction and maintenance dosing regimens.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
/Age/Gender
Adult participants≥18 years of age at the time of signing the Informed Consent Form (ICF).
Type of Participants and Disease
Symptomatic during run-in, defined by the following:
Participants must complete daily PRO assessments and meet the following compliance criteria:
Compliance with the locally-approved dose of antihistamine, maintained at randomisation.
Reproduction
Females of (FOCBP) must agree to use a highly effective method of (confirmed by the Investigator) from randomisation, throughout the study duration, and within12 weeks after last dose of IP and have a negative serum pregnancy test result on Visit 1. Highly effective methods of birth control include:
Females not of childbearing potential are defined as Females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are . Females will be considered postmenopausal if they have been amenorrhoeic for≥12 months prior to the planned date of randomisation without an alternative medical cause. The following age-specific requirements apply:
Exclusion Criteria:
Medical Conditions
Current active liver disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
Biological: Benralizumab
Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
Biological: Benralizumab
Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
Biological: Benralizumab
Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
Biological: Benralizumab
Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
Biological: Placebo and Benralizumab
2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Also known as: Benralizumab, Benra, Fasenra
2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Also known as: Benralizumab, Benra, Fasenra
Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12
The urticaria participant daily diary (UPDD) was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the itch severity score (ISS). The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day -1) and Week 12
LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the UAS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day -1) and Weeks 12 and 24
LS Mean Change From Baseline in ISS7 at Week 24
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the ISS. The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day -1) and Week 24
Percentage of Responders at Weeks 12 and 24
Responder was defined as a participant whose condition was considered clinically well controlled with UAS7 \<=6 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.
Time frame: Weeks 12 and 24
LS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the HSS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The HSS7 is the sum of hives severity score for the previous 7 days. The HSS7 represents hives severity on a scale from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of hives. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day -1) and Weeks 12 and 24
Time to >=5-Point Decrease in ISS7
The time to \>=5-point decrease (clinically relevant decrease) in ISS7 was reported. The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch.
Time frame: From Baseline (Day -1) up to Week 24
Percentage of Participants With Complete UAS7 Response at Weeks 12 and 24
Complete response was defined as participants with UAS7= 0 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.
Time frame: Weeks 12 and 24
Mean Percentage of Angioedema-Free Days Over the Past 7 Days at Weeks 12 and 24
The UPDD included a daily yes/no question asking whether the participant experienced angioedema during the past 24 hours. If yes, the participant was asked a follow-up question about how they treated the swelling. The percentage of angioedema-free days was calculated over the past 7 days by (number of angioedema-free days/number of non-missing responses) x 100.
Time frame: Weeks 12 and 24
LS Mean Change From Baseline in Urticaria Control Test (UCT) at Weeks 12 and 24
Urticaria disease control was assessed by the UCT using the electronic participant-reported outcome device. The UCT has a retrospective approach using a recall period of 4 weeks and responses on 5-point Likert scales with score ranging from 0 to 4 for each question. Subsequently, the scores for all 4 questions were summed up. The UCT scale range from 0 (minimum) to 16 (maximum). Higher scores indicate better disease control.
Time frame: Baseline (Day -1) and Weeks 12 and 24
LS Mean Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Weeks 12 and 24
The CU-Q2oL is a 23-item assessment of CSU-specific health-related quality of life. Participants were asked to rate their CSU symptoms and the impact of their symptoms over the last 2 weeks on several domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. The questions were scored as 1= not at all, 2= a little, 3= moderately, 4= very much, 5= extremely. The scores were transformed into percentages of the maximum possible score. The CU-Q2oL scale range from 0 (minimum) to 100 (maximum). Higher scores indicate greater impact of urticaria on health-related quality of life.
Time frame: Baseline (Day -1) and Weeks 12 and 24
LS Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Weeks 12 and 24
The DLQI is a 10-item assessment of dermatology-specific health-related quality of life. Participants were asked to rate their symptoms and the impact of their symptoms over the last week on several domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The questions (except question 7) were scored on a 4-point Likert scale: 0= not at all, 1= a little, 2= a lot, 3= very much. Scoring question 7, the first part asked: 'Over the last week, has your skin prevented you from working or studying?' Scoring was for response of 0= not relevant and 3= yes. If response was 'no', a further question was asked: 'How much has your skin been a problem at work or studying', and scored as: 0= not at all, 1= a little, 2= a lot. The DLQI was calculated by summing the score of each question. The DLQI scale range from 0 (minimum) to 30 (maximum). Higher scores indicate greater impact on participant's life.
Time frame: Baseline (Day -1) and Weeks 12 and 24
Serum Concentration of Benralizumab
Blood samples were collected to determine the serum concentration of benralizumab.
Time frame: Pre-dose on Weeks 4, 12 and 24
Number of Participants With Anti-Drug Antibody (ADA) Response to Benralizumab
Blood samples were measured for the presence of ADAs for benralizumab using validated assays. The ADA incidence (treatment-emergent ADA positive) was defined as ADA negative at baseline and post-baseline ADA positive, or ADA positive at baseline and boosted the pre-existing titre by \> 4-fold during the study period. Persistently positive was defined as ADA negative at baseline and positive at \>= 2 post-baseline assessments (with \>= 16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as ADA negative at baseline, having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. The median of maximum titres was calculated based on the maximum titre for each ADA positive participant within each treatment group (including both baseline and post-baseline measurements).
Time frame: Pre-dose on Weeks 12 and 24
This Phase 2b, randomized, double-blind study was conducted in participants with chronic spontaneous urticaria (CSU) who were symptomatic despite the use of antihistamines at 46 study centers in Bulgaria, Germany, Japan, Korea, Poland, Spain, and United States of America between 27 October 2020 and 28 March 2023. The study was terminated early by the sponsor as primary results did not support the continued development of benralizumab for the indication of CSU.
| Milestone | Double-blind Then Extension Period: Benralizumab 30 mg Q4W | Double-blind Then Extension Period: Benralizumab 30 mg Q8W | Double-blind Then Extension Period: Benralizumab 60 mg Q4W | Double-blind Then Extension Period: Benralizumab 60 mg Q8W | Double-blind Then Extension Period: Placebo |
|---|---|---|---|---|---|
| Started | 30 | 29 | 28 | 28 | 40 |
| Completed the treatment period | 26 | 27 | 25 | 28 | 37 |
| Entered extension period | 24 | 26 | 25 | 28 | 37 |
| Completed | 16 | 21 | 20 | 23 | 24 |
| Not completed | 14 | 8 | 8 | 5 | 16 |
| Withdrew: Adverse event | 1 | 3 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 1 | 2 | 4 | 5 |
| Withdrew: Withdrawal by subject | 8 | 3 | 5 | 1 | 9 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
The urticaria participant daily diary (UPDD) was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the itch severity score (ISS). The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12 | -7.50 (-8.94 to -6.05) | -8.28 (-9.76 to -6.80) | -6.49 (-8.24 to -4.74) |
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the UAS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | -14.48 (-17.58 to -11.38) | -16.77 (-19.94 to -13.59) | -12.41 (-16.17 to -8.65) |
| Week 24 | -17.99 (-21.29 to -14.68) | -19.17 (-22.51 to -15.83) | -15.43 (-19.43 to -11.44) |
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the ISS. The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| LS Mean Change From Baseline in ISS7 at Week 24 | -9.19 (-10.77 to -7.61) | -9.33 (-10.93 to -7.73) | -7.57 (-9.48 to -5.66) |
Responder was defined as a participant whose condition was considered clinically well controlled with UAS7 \<=6 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.
| percentage of participants | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | 22.0 | 21.4 | 10.0 |
| Week 24 | 28.8 | 37.5 | 27.5 |
The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the HSS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The HSS7 is the sum of hives severity score for the previous 7 days. The HSS7 represents hives severity on a scale from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of hives. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | -7.03 (-8.84 to -5.22) | -8.47 (-10.32 to -6.62) | -5.87 (-8.06 to -3.68) |
| Week 24 | -8.88 (-10.76 to -7.00) | -9.81 (-11.71 to -7.91) | -7.82 (-10.09 to -5.54) |
The time to \>=5-point decrease (clinically relevant decrease) in ISS7 was reported. The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch.
| weeks | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Time to >=5-Point Decrease in ISS7 | 3.0 (2.0 to 5.0) | 2.0 (2.0 to 3.0) | 8.0 (3.0 to 11.0) |
Complete response was defined as participants with UAS7= 0 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.
| percentage of participants | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | 11.9 | 7.1 | 10.0 |
| Week 24 | 16.9 | 21.4 | 20.0 |
The UPDD included a daily yes/no question asking whether the participant experienced angioedema during the past 24 hours. If yes, the participant was asked a follow-up question about how they treated the swelling. The percentage of angioedema-free days was calculated over the past 7 days by (number of angioedema-free days/number of non-missing responses) x 100.
| percentage of days | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | 77.50 ± 35.990 | 85.63 ± 32.435 | 81.93 ± 34.548 |
| Week 24 | 78.50 ± 36.992 | 91.33 ± 27.032 | 86.79 ± 31.798 |
Urticaria disease control was assessed by the UCT using the electronic participant-reported outcome device. The UCT has a retrospective approach using a recall period of 4 weeks and responses on 5-point Likert scales with score ranging from 0 to 4 for each question. Subsequently, the scores for all 4 questions were summed up. The UCT scale range from 0 (minimum) to 16 (maximum). Higher scores indicate better disease control.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | 4.74 (3.71 to 5.76) | 6.11 (5.05 to 7.17) | 5.02 (3.78 to 6.26) |
| Week 24 | 5.24 (4.04 to 6.45) | 6.87 (5.65 to 8.09) | 5.88 (4.44 to 7.32) |
The CU-Q2oL is a 23-item assessment of CSU-specific health-related quality of life. Participants were asked to rate their CSU symptoms and the impact of their symptoms over the last 2 weeks on several domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. The questions were scored as 1= not at all, 2= a little, 3= moderately, 4= very much, 5= extremely. The scores were transformed into percentages of the maximum possible score. The CU-Q2oL scale range from 0 (minimum) to 100 (maximum). Higher scores indicate greater impact of urticaria on health-related quality of life.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | -16.47 (-20.10 to -12.84) | -20.34 (-24.09 to -16.60) | -18.10 (-22.46 to -13.74) |
| Week 24 | -17.60 (-21.81 to -13.40) | -22.11 (-26.38 to -17.84) | -19.07 (-24.09 to -14.05) |
The DLQI is a 10-item assessment of dermatology-specific health-related quality of life. Participants were asked to rate their symptoms and the impact of their symptoms over the last week on several domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The questions (except question 7) were scored on a 4-point Likert scale: 0= not at all, 1= a little, 2= a lot, 3= very much. Scoring question 7, the first part asked: 'Over the last week, has your skin prevented you from working or studying?' Scoring was for response of 0= not relevant and 3= yes. If response was 'no', a further question was asked: 'How much has your skin been a problem at work or studying', and scored as: 0= not at all, 1= a little, 2= a lot. The DLQI was calculated by summing the score of each question. The DLQI scale range from 0 (minimum) to 30 (maximum). Higher scores indicate greater impact on participant's life.
| units on a scale | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 12 | -7.58 (-9.18 to -5.98) | -9.31 (-10.96 to -7.66) | -8.06 (-9.98 to -6.14) |
| Week 24 | -8.13 (-9.84 to -6.42) | -10.25 (-11.98 to -8.51) | -9.37 (-11.41 to -7.33) |
Blood samples were collected to determine the serum concentration of benralizumab.
| nanogram per milliliter (ng/mL) | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| Week 4 | 990.515 ± 448.6799 | 2167.606 ± 991.7509 | — |
| Week 12 | 1321.373 ± 740.5070 | 3145.352 ± 1577.6726 | — |
| Week 24 | 1372.806 ± 883.5830 | 1638.810 ± 946.9466 | NA ± NA |
Blood samples were measured for the presence of ADAs for benralizumab using validated assays. The ADA incidence (treatment-emergent ADA positive) was defined as ADA negative at baseline and post-baseline ADA positive, or ADA positive at baseline and boosted the pre-existing titre by \> 4-fold during the study period. Persistently positive was defined as ADA negative at baseline and positive at \>= 2 post-baseline assessments (with \>= 16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as ADA negative at baseline, having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. The median of maximum titres was calculated based on the maximum titre for each ADA positive participant within each treatment group (including both baseline and post-baseline measurements).
| Participants | Benralizumab 30 mg | Benralizumab 60 mg | Placebo |
|---|---|---|---|
| ADA prevalence | 18 | 13 | 4 |
| ADA negative (both baseline and post-baseline negative) | 37 | 41 | 33 |
| Only baseline positive | 1 | 1 | 0 |
| Baseline and at least 1 post-baseline positive | 3 | 4 | 0 |
| ADA incidence | 15 | 10 | 4 |
| ADA persistently positive | 10 | 4 | 4 |
| ADA transiently positive | 5 | 5 | 0 |
| ADA positive with maximum titre > median of maximum titres | 8 | 5 | 1 |
| ADA positive with maximum titre <= median of maximum titres | 10 | 8 | 3 |
Collected over Treatment-emergent adverse events (TEAEs) are reported from the first dose administration up to 30days after the last dose of study drug, a maximum of approximately 57 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Period: Benralizumab 30 mg Q4W | 0/59 (0%) | 3/59 (5.1%) | 14/59 (23.7%) |
| Double-blind Period: Benralizumab 60 mg Q4W | 0/56 (0%) | 1/56 (1.8%) | 13/56 (23.2%) |
| Double-blind Period: Placebo | 0/40 (0%) | 0/40 (0%) | 10/40 (25%) |
| Extension Period: Benralizumab 30 mg Q4W | 0/49 (0%) | 0/49 (0%) | 16/49 (32.7%) |
| Extension Period: Benralizumab 30 mg Q8W | 0/54 (0%) | 3/54 (5.6%) | 12/54 (22.2%) |
| Extension Period: Placebo to Benralizumab | 0/37 (0%) | 1/37 (2.7%) | 11/37 (29.7%) |
| Event | Double-blind Period: Benralizumab 30 mg Q4W | Double-blind Period: Benralizumab 60 mg Q4W | Double-blind Period: Placebo | Extension Period: Benralizumab 30 mg Q4W | Extension Period: Benralizumab 30 mg Q8W | Extension Period: Placebo to Benralizumab |
|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/59 | 0/56 | 0/40 | 0/49 | 0/54 | 1/37 |
| UreterolithiasisRenal and urinary disorders | 0/59 | 0/56 | 0/40 | 0/49 | 1/54 | 0/37 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/59 | 0/56 | 0/40 | 0/49 | 1/54 | 0/37 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/59 | 0/56 | 0/40 | 0/49 | 1/54 | 0/37 |
| UrticariaSkin and subcutaneous tissue disorders | 0/59 | 1/56 | 0/40 | 0/49 | 0/54 | 0/37 |
| Biliary colicHepatobiliary disorders | 1/59 | 0/56 | 0/40 | 0/49 | 0/54 | 0/37 |
| HypersensitivityImmune system disorders | 1/59 | 0/56 | 0/40 | 0/49 | 0/54 | 0/37 |
| Subarachnoid haemorrhageNervous system disorders | 1/59 | 0/56 | 0/40 | 0/49 | 0/54 | 0/37 |
| Event | Double-blind Period: Benralizumab 30 mg Q4W | Double-blind Period: Benralizumab 60 mg Q4W | Double-blind Period: Placebo | Extension Period: Benralizumab 30 mg Q4W | Extension Period: Benralizumab 30 mg Q8W | Extension Period: Placebo to Benralizumab |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 5/59 | 5/56 | 1/40 | 4/49 | 4/54 | 5/37 |
| NasopharyngitisInfections and infestations | 1/59 | 4/56 | 2/40 | 5/49 | 2/54 | 2/37 |
| SinusitisInfections and infestations | 2/59 | 0/56 | 1/40 | 1/49 | 0/54 | 3/37 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/59 | 0/56 | 2/40 | 0/49 | 1/54 | 3/37 |
| Ligament sprainInjury, poisoning and procedural complications | 0/59 | 0/56 | 1/40 | 3/49 | 1/54 | 0/37 |
| Back painMusculoskeletal and connective tissue disorders | 0/59 | 2/56 | 1/40 | 2/49 | 3/54 | 0/37 |
| HeadacheNervous system disorders | 3/59 | 3/56 | 2/40 | 2/49 | 1/54 | 1/37 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/59 | 1/56 | 1/40 | 1/49 | 0/54 | 0/37 |
The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug, irrespective of their protocol adherence and continued participation in the study.
| Age, Customized(Participants) | Benralizumab 30 mg | Benralizumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| <35 years | 11 | 15 | 8 | 34 |
| >=35 to <=55 years | 32 | 25 | 22 | 79 |
| >55 years | 16 | 16 | 10 | 42 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg | Benralizumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 44 | 45 | 25 | 114 |
| Male | 15 | 11 | 15 | 41 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 30 mg | Benralizumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| White | 46 | 42 | 30 | 118 |
| Asian | 12 | 12 | 8 | 32 |
| Black or African American | 1 | 2 | 0 | 3 |
| Not reported | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Benralizumab 30 mg | Benralizumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 4 | 10 |
| Not Hispanic or Latino | 57 | 52 | 36 | 145 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2020 to primary completion in Oct 2022, 23 months.
Results were first posted in Mar 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab